Compare ADC Therapeutics SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 442 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.93
68.82%
-1.86
Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
-57 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
126.01%
0%
126.01%
6 Months
12.36%
0%
12.36%
1 Year
7.42%
0%
7.42%
2 Years
55.16%
0%
55.16%
3 Years
-41.38%
0%
-41.38%
4 Years
-82.4%
0%
-82.4%
5 Years
-89.59%
0%
-89.59%
ADC Therapeutics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
112.90%
EBIT Growth (5y)
11.20%
EBIT to Interest (avg)
-12.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
-0.41
Tax Ratio
0.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.63%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.62
EV to EBIT
-5.11
EV to EBITDA
-5.24
EV to Capital Employed
40.12
EV to Sales
8.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-785.24%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 17 Schemes (6.11%)
Foreign Institutions
Held by 19 Foreign Institutions (6.42%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
18.80
23.00
-18.26%
Operating Profit (PBDIT) excl Other Income
-30.20
-27.70
-9.03%
Interest
13.00
12.20
6.56%
Exceptional Items
-13.10
0.00
Consolidate Net Profit
-56.60
-38.60
-46.63%
Operating Profit Margin (Excl OI)
-1,648.50%
-1,235.80%
-41.27%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -18.26% vs 36.09% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -46.63% vs -25.73% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
70.80
69.60
1.72%
Operating Profit (PBDIT) excl Other Income
-127.40
-161.10
20.92%
Interest
50.20
46.30
8.42%
Exceptional Items
11.50
3.90
194.87%
Consolidate Net Profit
-157.80
-240.10
34.28%
Operating Profit Margin (Excl OI)
-1,844.40%
-2,363.20%
51.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.72% vs -66.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 34.28% vs -52.83% in Dec 2023
About ADC Therapeutics SA 
ADC Therapeutics SA
Pharmaceuticals & Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Company Coordinates 
Company Details
Biopole, route de la Corniche 3B , EPALINGES None : 1066
Registrar Details






